학술논문
Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.
Document Type
Article
Author
Suzuki, Kazuhito; Mizuno, Shohei; Shimazu, Yutaka; Fuchida, Shin‐ichi; Hagiwara, Shotaro; Itagaki, Mitsuhiro; Nishiwaki, Kaichi; Hangaishi, Akira; Karasuno, Takahiro; Kikuchi, Taku; Shimizu, Misayo; Nishikawa, Akinori; Kobayashi, Takeshi; Sunami, Kazutaka; Hiramoto, Nobuhiro; Uchiyama, Hitoji; Maruyama, Yumiko; Kanda, Yoshinobu; Ichinohe, Tatsuo; Atsuta, Yoshiko
Source
Subject
*OLDER patients
*STEM cell transplantation
*MULTIPLE myeloma
*CELLULAR therapy
*RETROSPECTIVE studies
*
*
*
*
Language
ISSN
0902-4441
Abstract
Tandem autologous stem cell transplantation (ASCT) has been reconsidered for high‐risk patients with myeloma, and the eligibility criteria for up‐front ASCT have been updated to include more elderly patients. This study aimed to evaluate the efficacy and tolerability of tandem ASCT in elderly patients with myeloma compared to tandem ASCT in young patients and single ASCT in elderly patients. A retrospective study using the Transplant Registry Unified Management Program database of the Japanese Society for Transplantation and Cellular Therapy, which included 64 elderly and 613 young patients who received tandem ASCT, and 891 elderly patients who received single ASCT, was conducted. The median overall survival (OS) over 38.5 months in the elderly and young patients who received tandem ASCT, and elderly patients who received single ASCT was 78.9, 92.5, and 77.1 months, respectively; no significant difference in the median OS was observed. The cumulative incidence of transplantation‐related mortality was similar in the elderly and young patients receiving tandem ASCT. High‐risk cytogenetic abnormality was not identified as a poor prognostic factor for OS in elderly patients who received tandem ASCT but in those who received single ASCT. Thus, tandem ASCT was effective and tolerable in elderly patients with myeloma. [ABSTRACT FROM AUTHOR]